Frances A. Shepherd
University Health Network · 1,109 works · 81,778 citations · h-index 129
Top works
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- Characterizing the cancer genome in lung adenocarcinoma
- Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
- Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
- Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
- Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
- A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial
- Second-Line Treatment of Advanced Non-small Cell Lung Cancer
- Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer